Monitor ATLAS trial data readouts for efficacy signals; a positive Phase II/III result could significantly expand momelotinib's addressable market. Near-term stock impact likely muted as ODD is an early milestone with no revenue contribution.
GSK drugs
GSK drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jun 12 $53.04entry
- T+1 · 5mo ago −1.53%α −3.29% · $52.23
- T+5 · 5mo ago −4.47%α −5.14% · $50.67
- T+20 · 4mo ago −0.49%α −2.27% · $52.78
- T+60 · 2mo ago −8.48%α −11.75% · $48.54
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
GSK announced that momelotinib received Orphan Drug Designation (ODD) from the FDA and EMA for VEXAS syndrome, a rare life-threatening condition with no approved treatments. The designation supports the ongoing phase II/III ATLAS trial and potential future regulatory submissions, expanding momelotinib's development program beyond myelofibrosis.
Key Facts
- Momelotinib granted Orphan Drug Designation (ODD) by FDA and EMA for VEXAS syndrome.
- VEXAS syndrome has a 30-40% five-year mortality rate and no approved treatments.
- Phase II/III ATLAS trial evaluating momelotinib in VEXAS is underway; study design presented at EHA Congress June 11-14, 2026.
- Momelotinib is already approved for myelofibrosis in the US, EU, UK, and Japan.
Financial Impact
No revenue impact yet; potential future revenue if approved for VEXAS, but current VEXAS market size is small and uncertain.
Risk Factors
- Clinical trial failure or underwhelming efficacy data could derail VEXAS indication.
- VEXAS syndrome is ultra-rare, limiting commercial upside even if approved.
- Competing therapies may emerge before ATLAS trial completes.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001654954-26-005913 |
| Document: 0001654954-26-005913-index-headers.html | 0001654954-26-005913 |
| Document: 0001654954-26-005913-index.html | 0001654954-26-005913 |
| Document: 0001654954-26-005913.txt | 0001654954-26-005913 |
Track record
64 reports on GSK
9 of 17 bullish or bearish reports moved the stock their way by T+20. Best: +9.35% at T+60 after the Jul 17, 2026 report. 15 of 20 went positive at some point.
Filters
- Nov 13, 20263d ago 6-K Neutral 4/10 Entry $50.45 Now $50.41 −0.08% settles Dec 14
- Nov 12, 20264d ago 6-K Neutral 2/10 Entry $50.64 Now $50.41 −0.45% settles Dec 11
- Nov 6, 202610d ago 6-K Neutral 1/10 Entry $50.33 Now $50.41 +0.16% settles Dec 7
- Nov 2, 202614d ago 6-K Neutral 1/10 Entry $49.13 Now $50.41 +2.61% settles Dec 1
- Oct 28, 202619d ago 6-K Neutral 5/10 Entry $48.74 Now $50.41 +3.43% settles Nov 25
- Oct 26, 202621d ago 6-K Bullish 5/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
- Oct 26, 202621d ago 6-K Neutral 1/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
- Oct 26, 202621d ago 6-K Bullish 5/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
- Oct 26, 202621d ago 6-K Neutral 4/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
- Oct 21, 202626d ago 6-K Bullish 7/10 Entry $50.02 Now $50.41 +0.78% settles Nov 18
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers